glp-1 drug market New Demand in an Old GLP-1 Receptor Agonist Market Size

doi:10.1001/jama.2024.10333 2

Brainstem mechanisms of amylin-induced anorexia

The analysis included 3,845,171 patients with type 2 diabetes, of whom 15.1% were prescribed a GLP-1 RA, including 6.6% who received dulaglutide, 4.9% who received semaglutide, 4.2% who received liraglutide, and 2.1% who received exenatide

The genetic test identifies variants associated with appetite regulation, insulin secretion, and metabolic flexibilitydomains where prescription GLP-1 therapies have documented clinical benefit

In West Virginia, the Public Employees Insurance Agency (PEIA) started a 1,000 person pilot program that covered GLP-1s to treat obesity beginning in 2019

Conclusions The currently available evidence on the mechanisms of action and clinical effects of GLP-1/GIP dual agonism supports very optimistic prospects for the future use of tirzepatide